NCT03197506View on ClinicalTrials.gov

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

July 16, 2024

Study Completion Date

June 6, 2028

Conditions
GlioblastomaGliosarcomaSupratentorial Glioblastoma
Interventions
RADIATION

External Beam Radiation Therapy

Undergo external beam radiation therapy

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Temozolomide

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (3)

55905

Mayo Clinic in Rochester, Rochester

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER